B. Riley Wealth Advisors’s AbCellera Biologics ABCL Stock Holding History

B. Riley Wealth Advisors’s Portfolio ABCL Stock Details ABCL Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	–	Sell	-50,000	Closed	-$1.64K	–	916
2026 Q1	$1.64K	Buy	+50,000	New	+$180K	﹤0.01%	891
2025 Q4	–	Sell	-50,000	Closed	-$2.52K	–	1021
2025 Q3	$2.52K	Buy	+50,000	New	+$220K	﹤0.01%	1071

Other funds holding ABCL

BBA

Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return

Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

TWC

TD Waterhouse Canada Toronto, Ontario, Canada $38B AUM 39.14% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

UBS AM Chicago, Illinois $550B AUM 43.33% 1-Year Est. Return

ACH

ArrowMark Colorado Holdings Denver, Colorado $2.4B AUM 42.85% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

DCM

Driehaus Capital Management Chicago, Illinois $17.3B AUM 211.34% 1-Year Est. Return

Tudor Investment Corp Stamford, Connecticut $71.9B AUM 42.37% 1-Year Est. Return

B. Riley Wealth Advisors's ABCL Position: Q2 2026 in Review

B. Riley Wealth Advisors sold out of AbCellera Biologics (ABCL) in Q2 2026, closing a stake of 500 shares — an estimated $1.64K sold.

B. Riley Wealth Advisors first reported a position in ABCL in Q3 2023 and held it in 7 quarters. The position peaked at $111K in Q4 2023. 150 funds tracked by Wall St. Rank hold ABCL as of Q2 2026.

B. Riley Wealth Advisors reported no remaining AbCellera Biologics position as of Q2 2026 after selling out during the quarter.
B. Riley Wealth Advisors sold 500 AbCellera Biologics shares in Q2 2026, an estimated $1.64K.
B. Riley Wealth Advisors first reported a position in AbCellera Biologics in Q3 2023 and held it in 7 quarters.
B. Riley Wealth Advisors's AbCellera Biologics position peaked at $111K in Q4 2023.
150 funds tracked by Wall St. Rank held AbCellera Biologics as of Q2 2026.

Based on B. Riley Wealth Advisors's 13F filing for Q2 2026, filed 14 Jul 2026.